126 related articles for article (PubMed ID: 32387312)
21. Steroid/mucokinetic hybrid nanoporous microparticles for pulmonary drug delivery.
Tewes F; Paluch KJ; Tajber L; Gulati K; Kalantri D; Ehrhardt C; Healy AM
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):604-13. PubMed ID: 23563102
[TBL] [Abstract][Full Text] [Related]
22. Investigation of drug dissolution and uptake from low-density DPI formulations in an impactor-integrated cell culture model.
Šimková K; Thormann U; Imanidis G
Eur J Pharm Biopharm; 2020 Oct; 155():12-21. PubMed ID: 32717388
[TBL] [Abstract][Full Text] [Related]
23. Application of a One-Dimensional Computational Model for the Prediction of Deposition from a Dry Powder Inhaler.
Gourgoulianis K; Daniil Z; Athanasiou K; Rozou S; Bontozoglou V
J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):435-443. PubMed ID: 28683222
[TBL] [Abstract][Full Text] [Related]
24. Aerodynamic deposition of combination dry powder inhaler formulations in vitro: a comparison of three impactors.
Taki M; Marriott C; Zeng XM; Martin GP
Int J Pharm; 2010 Mar; 388(1-2):40-51. PubMed ID: 20026261
[TBL] [Abstract][Full Text] [Related]
25. The Influence of Electrostatic Controls on MDI Size Distribution Measurements.
Stein SW; Rasmussen J; Walls S; Schultz DW; Oakley C; Drake JB
AAPS PharmSciTech; 2019 Apr; 20(5):170. PubMed ID: 31004248
[TBL] [Abstract][Full Text] [Related]
26. Modelling the bronchial barrier in pulmonary drug delivery: A human bronchial epithelial cell line supplemented with human tracheal mucus.
Murgia X; Yasar H; Carvalho-Wodarz C; Loretz B; Gordon S; Schwarzkopf K; Schaefer U; Lehr CM
Eur J Pharm Biopharm; 2017 Sep; 118():79-88. PubMed ID: 28373109
[TBL] [Abstract][Full Text] [Related]
27. The formulation of a pressurized metered dose inhaler containing theophylline for inhalation.
Zhu B; Haghi M; Goud M; Young PM; Traini D
Eur J Pharm Sci; 2015 Aug; 76():68-72. PubMed ID: 25956075
[TBL] [Abstract][Full Text] [Related]
28. Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). Part I: Design.
Marple VA; Roberts DL; Romay FJ; Miller NC; Truman KG; Van Oort M; Olsson B; Holroyd MJ; Mitchell JP; Hochrainer D
J Aerosol Med; 2003; 16(3):283-99. PubMed ID: 14572326
[TBL] [Abstract][Full Text] [Related]
29. A new Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulations.
Hein S; Bur M; Schaefer UF; Lehr CM
Eur J Pharm Biopharm; 2011 Jan; 77(1):132-8. PubMed ID: 20951200
[TBL] [Abstract][Full Text] [Related]
30. Permeability characteristics of calu-3 human bronchial epithelial cells: in vitro-in vivo correlation to predict lung absorption in rats.
Mathia NR; Timoszyk J; Stetsko PI; Megill JR; Smith RL; Wall DA
J Drug Target; 2002 Feb; 10(1):31-40. PubMed ID: 11996084
[TBL] [Abstract][Full Text] [Related]
31. Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane-134a beclomethasone in asthmatic patients.
Leach CL; Kuehl PJ; Chand R; Ketai L; Norenberg JP; McDonald JD
Ann Allergy Asthma Immunol; 2012 Mar; 108(3):195-200. PubMed ID: 22374204
[TBL] [Abstract][Full Text] [Related]
32. Dissolution of fine particle fraction from truncated Anderson cascade impactor with an enhancer cell.
Tay JYS; Liew CV; Heng PWS
Int J Pharm; 2018 Jul; 545(1-2):45-50. PubMed ID: 29689370
[TBL] [Abstract][Full Text] [Related]
33. Adapting the Abbreviated Impactor Measurement (AIM) concept to make appropriate inhaler aerosol measurements to compare with clinical data: a scoping study with the "Alberta" idealized throat (AIT) inlet.
Mitchell J; Copley M; Sizer Y; Russell T; Solomon D
J Aerosol Med Pulm Drug Deliv; 2012 Aug; 25(4):188-97. PubMed ID: 22857270
[TBL] [Abstract][Full Text] [Related]
34. The permeability of large molecular weight solutes following particle delivery to air-interfaced cells that model the respiratory mucosa.
Grainger CI; Greenwell LL; Martin GP; Forbes B
Eur J Pharm Biopharm; 2009 Feb; 71(2):318-24. PubMed ID: 18845252
[TBL] [Abstract][Full Text] [Related]
35. Towards the bioequivalence of pressurised metered dose inhalers 2. Aerodynamically equivalent particles (with and without glycerol) exhibit different biopharmaceutical profiles in vitro.
Haghi M; Bebawy M; Colombo P; Forbes B; Lewis DA; Salama R; Traini D; Young PM
Eur J Pharm Biopharm; 2014 Jan; 86(1):38-45. PubMed ID: 23528797
[TBL] [Abstract][Full Text] [Related]
36. Addressing the Need for Controls on Particle Bounce and Re-entrainment in the Cascade Impactor and for the Mitigation of Electrostatic Charge for Aerodynamic Particle Size Assessment of Orally Inhaled Products: an Assessment by the International Consortium on Regulation and Science (IPAC-RS).
Doub W; Stein S; Mitchell J; Goodey AP
AAPS PharmSciTech; 2020 Aug; 21(7):239. PubMed ID: 32827121
[TBL] [Abstract][Full Text] [Related]
37. Effect of USP Induction Ports, Glass Sampling Apparatus, and Inhaler Device Resistance on Aerodynamic Patterns of Fluticasone Propionate-Loaded Engineered Mannitol Microparticles.
Mehta P; Bothiraja C; Kadam S; Pawar A
AAPS PharmSciTech; 2019 May; 20(5):197. PubMed ID: 31123855
[TBL] [Abstract][Full Text] [Related]
38. Electrostatic charge characteristics of aerosols produced from metered dose inhalers.
Kwok PC; Glover W; Chan HK
J Pharm Sci; 2005 Dec; 94(12):2789-99. PubMed ID: 16258995
[TBL] [Abstract][Full Text] [Related]
39. In vitro, ex vivo and in vivo methods of lung absorption for inhaled drugs.
Sakagami M
Adv Drug Deliv Rev; 2020; 161-162():63-74. PubMed ID: 32763274
[TBL] [Abstract][Full Text] [Related]
40. Inhalable tranexamic acid for haemoptysis treatment.
Haghi M; van den Oetelaar W; Moir LM; Zhu B; Phillips G; Crapper J; Young PM; Traini D
Eur J Pharm Biopharm; 2015 Jun; 93():311-9. PubMed ID: 25936858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
